Compare ODC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | PHAR |
|---|---|---|
| Founded | 1941 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | ODC | PHAR |
|---|---|---|
| Price | $49.70 | $18.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 89.6K | 23.4K |
| Earning Date | 12-08-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | 0.00 |
| Revenue | ★ $478,113,000.00 | $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | N/A | $4.47 |
| P/E Ratio | ★ $13.63 | $3,043.51 |
| Revenue Growth | 5.29 | ★ 26.78 |
| 52 Week Low | $40.66 | $7.50 |
| 52 Week High | $69.76 | $18.12 |
| Indicator | ODC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 59.57 |
| Support Level | $45.61 | $16.98 |
| Resistance Level | $54.16 | $17.00 |
| Average True Range (ATR) | 2.32 | 0.71 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.78 | 98.48 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.